131 related articles for article (PubMed ID: 3937188)
1. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
[TBL] [Abstract][Full Text] [Related]
2. [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Grosset J; Truffot C; Fermanian J; Lecoeur H
Pathol Biol (Paris); 1982 Jun; 30(6):444-8. PubMed ID: 6810288
[TBL] [Abstract][Full Text] [Related]
3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
4. [Phenotypic characterization of pyrazinamide-resistant Mycobacterium tuberculosis isolated in Poland].
Napiórkowska A; Augustynowicz-Kopeć E; Zwolska Z
Pneumonol Alergol Pol; 2010; 78(4):256-62. PubMed ID: 20665445
[TBL] [Abstract][Full Text] [Related]
5. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Lecoeur HF; Truffot-Pernot C; Grosset JH
Am Rev Respir Dis; 1989 Nov; 140(5):1189-93. PubMed ID: 2817579
[TBL] [Abstract][Full Text] [Related]
6. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
7. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
[TBL] [Abstract][Full Text] [Related]
8. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Grosset J; Truffot-Pernot C; Lacroix C; Ji B
Antimicrob Agents Chemother; 1992 Mar; 36(3):548-51. PubMed ID: 1622164
[TBL] [Abstract][Full Text] [Related]
9. [Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].
Truffot-Pernot C; Grosset J; Bismuth R; Lecoeur H
Rev Fr Mal Respir; 1983; 11(6):875-82. PubMed ID: 6669798
[TBL] [Abstract][Full Text] [Related]
10. [Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice].
Grosset J; Truffot-Pernot C; Lecoeur H; Guelpa-Lauras CC
Pathol Biol (Paris); 1983 May; 31(5):446-50. PubMed ID: 6353339
[TBL] [Abstract][Full Text] [Related]
11. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
Byrne ST; Denkin SM; Zhang Y
J Antimicrob Chemother; 2007 Feb; 59(2):313-6. PubMed ID: 17185297
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil.
Höfling CC; Pavan EM; Giampaglia CM; Ferrazoli L; Aily DC; de Albuquerque DM; Ramos MC
Int J Tuberc Lung Dis; 2005 Jan; 9(1):87-93. PubMed ID: 15675556
[TBL] [Abstract][Full Text] [Related]
13. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice.
Lecoeur HF; Lagrange PH; Truffot-Pernot C; Gheorghiu M; Grosset J
Clin Exp Immunol; 1989 Jun; 76(3):458-62. PubMed ID: 2502336
[TBL] [Abstract][Full Text] [Related]
14. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Daniel N; Lounis N; Ji B; O'Brien RJ; Vernon A; Geiter LJ; Szpytma M; Truffot-Pernot C; Hejblum G; Grosset J
Am J Respir Crit Care Med; 2000 May; 161(5):1572-7. PubMed ID: 10806157
[TBL] [Abstract][Full Text] [Related]
15. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
Su WJ; Perng RP
Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
[TBL] [Abstract][Full Text] [Related]
18. [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Brändli O; Dreher D; Morger D
Schweiz Med Wochenschr; 1993 Jun; 123(25):1300-6. PubMed ID: 8341998
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
Hu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Liu Y; Schipani A; Davies G; Coates A
Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
Yee DP; Menzies D; Brassard P
Int J Tuberc Lung Dis; 2012 May; 16(5):604-9. PubMed ID: 22409887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
